Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumours (MK-5618-001)

Official Title

A Phase 1b Multi-centre Clinical Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumours.

Summary:

This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumours.

Trial Description

Primary Outcome:

• Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
• Number of Participants Experiencing an Adverse Event (AE)
• Number of Participants Discontinuing Study Treatment due to an Adverse Event

• Area Under the Concentration-Time Curve (AUC) of Selumetinib
• Maximum Observed Plasma Concentration (Cmax) of Selumetinib
• Minimum Observed Plasma Concentration (Cmin) of Selumetinib

View this trial on ClinicalTrials.gov